Who is sponsoring NCT04639388?

NCT04639388 is sponsored by Hôpital le Vinatier.

What drugs are being tested in NCT04639388?

Interventions in NCT04639388: neuropsychological testing, questionnaires and experimental tasks.

What condition does NCT04639388 study?

NCT04639388 studies 22q11.2 Deletion Syndrome.

Is NCT04639388 still recruiting?

NCT04639388 is currently recruiting now. Last updated 30 July 2025.

Last reviewed 2025-07-30 · How we verify

NCT04639388: PremiCeS22

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Understanding of Psychotic Disorders in Children With 22q11.2DS

Recruiting now NA Last updated 30 July 2025

What this trial tests

NA trial testing neuropsychological testing, questionnaires and experimental tasks in 22q11.2 Deletion Syndrome in 80 participants. Currently enrolling.

Timeline

13 November 2020

Primary endpoint
30 June 2026

30 September 2026

Quick facts

Lead sponsor	Hôpital le Vinatier
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	80
Start date	13 November 2020
Primary completion	30 June 2026
Estimated completion	30 September 2026
Sites	1 location across France

Drugs / interventions tested

neuropsychological testing, questionnaires and experimental tasks

Conditions studied

22q11.2 Deletion Syndrome — all drugs for 22q11.2 Deletion Syndrome →

Sponsor

Hôpital le Vinatier — full company profile →

Who can join

Adults 4 to 13, any sex, with 22q11.2 Deletion Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for 22q11.2 Deletion Syndrome

Currently open trials in the same condition.

NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting

Other Hôpital le Vinatier trials

Trials by the same sponsor.

NCT07428200 — Characterization of the Neural Bases of Mental Imagery in Individuals With Borderline Personality Disorder: An EEG Study · NA · not yet recruiting
NCT07384819 — Duration of Moment in Autism · NA · not yet recruiting
NCT06284382 — Interaction Between Early Trauma and Odor-induced Dopamine Release · NA · not yet recruiting
NCT07119671 — Peer-aid and Hope Box · NA · not yet recruiting
NCT06869915 — Homelessness and Prevalence of Neurodevelopmental Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04639388 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hôpital le Vinatier
Last refreshed: 30 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04639388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing